Enzymatic synthesis of chiral intermediates for pharmaceuticals

Ramesh Patel; Ronald Hanson; Animesh Goswami; Venkata Nanduri; Amit Banerjee; Mary-Jo Donovan; Steven Goldberg; Robert Johnston; David Brzozowski; Thomas Tully; Jeffrey Howell; Dana Cazzulino; Rapheal Ko

doi:10.1007/s10295-003-0032-6

Enzymatic synthesis of chiral intermediates for pharmaceuticals

J Ind Microbiol Biotechnol. 2003 May;30(5):252-9. doi: 10.1007/s10295-003-0032-6. Epub 2003 Mar 25.

Authors

Ramesh Patel¹, Ronald Hanson, Animesh Goswami, Venkata Nanduri, Amit Banerjee, Mary-Jo Donovan, Steven Goldberg, Robert Johnston, David Brzozowski, Thomas Tully, Jeffrey Howell, Dana Cazzulino, Rapheal Ko

Affiliation

¹ Process Research and Development, Bristol-Myers Squibb Pharmaceutical Research Institute, New Brunswick, New Jersey, 08903, USA. [email protected]

PMID: 12687489
DOI: 10.1007/s10295-003-0032-6

Abstract

There has been an increasing awareness of the enormous potential of microorganisms and enzymes for the transformation of synthetic chemicals with high chemo-, regio- and enatioselective manner. Chiral intermediates are in high demand by pharmaceutical industries for the preparation bulk drug substances. In this review article, microbial/enzymatic processes for the synthesis of chiral intermediates for antihypertensive drugs, melatonin receptor agonists, and beta3-receptor receptor agonists are described.

Publication types

Review

MeSH terms

Adrenergic beta-3 Receptor Agonists*
Adrenergic beta-Agonists / metabolism*
Antihypertensive Agents / metabolism*
Biotransformation
Chemistry, Pharmaceutical
Enzymes / metabolism*
Receptors, Cell Surface / agonists*
Receptors, Cell Surface / metabolism*
Receptors, Cytoplasmic and Nuclear / agonists*
Receptors, Cytoplasmic and Nuclear / metabolism*
Receptors, Melatonin
Stereoisomerism

Substances

Adrenergic beta-3 Receptor Agonists
Adrenergic beta-Agonists
Antihypertensive Agents
Enzymes
Receptors, Cell Surface
Receptors, Cytoplasmic and Nuclear
Receptors, Melatonin